# Trial of THEO-260 in Ovarian Cancer Patients

Source: https://onco.cc/trials/nct06618235/  
OnCo record `nct06618235` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of THEO-260 in ovarian cancer, run by Theolytics Limited, now recruiting.

## Summary

Trial of THEO-260 in Ovarian Cancer Patients is a phase 1/2 interventional study registered as NCT06618235 by Theolytics Limited, with 44 participants planned, started 2024-09-24 and due to reach its primary completion in 2028-06. Interventions recorded: THEO-260.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06618235
- Phase: 1/2
- Setting: A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer
- Sponsor: Theolytics Limited
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT06618235: https://clinicaltrials.gov/study/NCT06618235

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [THEO-260](https://onco.cc/drugs/theo-260/)

---
JSON: https://onco.cc/api/v1/entities/nct06618235.json